LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Rhea-AI Summary

LENZ Therapeutics (Nasdaq: LENZ) will report third quarter 2025 financial results and recent corporate highlights on Wednesday, November 5, 2025 at 8:30 a.m. EST via live webcast and conference call.

The company is a pharmaceutical firm commercializing VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults. Participants may join by phone (Domestic: (800) 715-9871; International: (646) 307-1963) using access code 1685282. The live webcast is available on LENZ Therapeutics’ investor website and a replay will be posted for 30 days after the event.

News Market Reaction

-0.55%

2 alerts

-0.55% News Effect

-$5M Valuation Impact

$869M Market Cap

0.6x Rel. Volume

On the day this news was published, LENZ declined 0.55%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $869M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Wednesday, November 5, 2025, at 8:30 a.m. EST to report its third quarter 2025 financial results and recent corporate highlights.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1685282. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

FAQ

When will LENZ Therapeutics (LENZ) report Q3 2025 results?

LENZ will report Q3 2025 results on Wednesday, November 5, 2025 at 8:30 a.m. EST via webcast and conference call.

How can I join the LENZ (LENZ) webcast and conference call on November 5, 2025?

Join the live webcast on LENZ’s investor website or call Domestic (800) 715-9871 / International (646) 307-1963 and enter access code 1685282.

Where will the LENZ (LENZ) webcast replay be available and for how long?

A replay will be available on the company’s investor website for 30 days following the November 5, 2025 event.

What product will LENZ discuss in its Q3 2025 corporate highlights?

LENZ is commercializing VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine eye drop for presbyopia in adults.

What is the conference call access code for LENZ’s November 5, 2025 call?

The access code for the conference call is 1685282.